tiprankstipranks
Trending News
More News >

Wolfe downgrades Vertex Pharmaceuticals on slow pain launch

Wolfe Research analyst Andy Chen last night downgraded Vertex Pharmaceuticals (VRTX) to Peer Perform from Outperform without a price target The company’s Q1 earnings reported slower cystic fibrosis revenue and a relatively slow nonopioid pain launch, the analyst tells investors in a research note. The firm says that despite yesterday’s selloff, it still believes there may be $45 to $80 worth of pain in the stock, and that “this may be hard to justify.” Wolfe predicts Vertex’s quarterly revenue on pain will continue to be the main stock driver.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue